Noncardiac comorbidities and intensive up ‐titration of oral treatment in patients recently hospitalized for heart failure: insights from the STRONG‐HF trial

ConclusionsIn the STRONG-HF trial, non-cardiac comorbidities neither limited the rapid up-titration of HF-therapies, nor attenuated the benefit of HIC on primary endpoint.In the context of a clinical trial, the benefit-risk ratio favors the rapid up-titration of HF-therapies even in patients with multiple NCCsThis article is protected by copyright. All rights reserved.

Source: European Journal of Heart Failure - September 21, 2023 Category: Cardiology Authors: Ovidiu Chioncel, Beth Davison, Marianna Adamo, Laura E Antohi, Mattia Arrigo, Marianela Barros, Jan Biegus, Kamil ė Čerlinskaitė‐Bajorė, Jelena Celutkiene, Alain Cohen‐Solal, Albertino Damasceno, Rafael Diaz, Christopher Edwards, Gera Tags: Research Article Source Type: research